Tritonix.ai

News / Korea / yonhap_finance

Daewoong Pharmaceutical Shares Slide 7% on Increased Damages Claim from Medytox

Health Technology · Biotechnology · yonhap_finance · 2026-09-03

069620, 086900

Daewoong Pharmaceutical shares fell over 7% after Medytox increased its damages claim in their ongoing botulinum toxin legal battle to 500 billion won.

What Happened

Increased Legal Claims: Daewoong Pharmaceutical announced that Medytox has increased its damages claim in their ongoing appellate lawsuit regarding trade secret misappropriation to 500 billion won. This amount represents approximately 44% of Daewoong's consolidated equity from the previous year.

Market Reaction: Following the disclosure, Daewoong Pharmaceutical's stock price dropped by 7.49% to close at 114,800 won. Investors reacted negatively to the news, reflecting concerns over the potential financial impact of the expanded litigation.

Background of Dispute: The legal conflict began in 2017 when Medytox accused Daewoong of stealing its botulinum strain and manufacturing processes. In 2023, a lower court ruled partially against Daewoong, ordering 40 billion won in damages, which triggered an appeal from the company.

Company Stance: Daewoong Pharmaceutical clarified that the updated claim amount is merely the plaintiff's demand and not a court-determined liability. The company remains in the appellate process and has successfully obtained a stay of execution regarding the initial court ruling.

Read original

More in Health Technology

Taiho Oncology's Anti-Thrombotic Film Enters FDA Review, Targeting 2026 Launch

Health Technology · economic_daily · 2026-09-06

Taiho Oncology's BEQIA anti-thrombotic film has entered standard FDA review, with a target completion date of April 22 next year.

6467

Adimmune August Revenue Grows 34% YoY

Health Technology · cnyes · 2026-09-04

Adimmune (4142) reported August revenue of NT$97.92 million, a 34.46% year-over-year increase, showing resilience compared to the biotech sector index.

4142

Huaan Plans $300 Million Capital Raise to Accelerate Drug Trials and Licensing

Health Technology · cnyes · 2026-09-04

Taiwan-based Huaan (6657) is set to raise NT$300 million through a new share issuance to fund clinical trials for its F705PD and F703EB drug candidates.

6657

Latest in Korea

U.S. Financial System Faces 'Backdoor' as Billions in Iranian Funds Bypass Sanctions

Finance · yonhap_finance · 2026-09-06

Despite strict U.S. sanctions, billions of dollars in Iranian funds are flowing through American banks annually by leveraging shell companies and foreign intermediaries.

FSS Tightens Rules on Target-Date Funds and Bank Loan Notifications

Finance · yonhap_finance · 2026-09-06

South Korea's financial regulator is strengthening disclosure requirements for target-date funds and mandating prior notice for bank loan suspensions.

New System to Instantly Block Deceased Individuals' Financial Transactions

Finance · yonhap_finance · 2026-09-06

Starting September 11, South Korea will launch a system that automatically blocks all financial transactions under a deceased person's name.

FSS Launches 'Voice Phishing Prevention Week' Across Financial Sector

Finance · yonhap_finance · 2026-09-06

The Financial Supervisory Service is partnering with major financial associations to host a week-long campaign focused on preventing voice phishing scams.